Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate settlement with Gilead Sciences, Inc. over an illegal kickback scheme to ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Washington has long failed to come up with a solution for rising drug prices that addresses the concerns of drugmakers, ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...

On Stocktwits, retail sentiment around Pheton is trending in the ‘extremely bullish’ territory, coupled with ‘extremely high’ ...

Review the current Gilead Sciences Inc (GILD:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if GILD is the best investment for you.